AgenciesAmid deteriorating Covid-19 situation in the country, the Centre on Friday granted permission to Indian Immunologicals Ltd, Hyderabad and Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr to manufacture Bharat Biotech's Covid-19 vaccine Covaxin.
The state-run Public Sector Undertaking (PSUs) will manufacture the drug on the basis of transfer of technology. “The government of India will be supporting to prepare their facility to provide 10-15 million doses per month by August-September,” the government said in a statement.
The Department of Science and Technology had on Thursday granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis," the Maharashtra Chief Minister's Office tweeted.
“Financial support to the tune of approximately Rs 65 crore will be provided for this facility to be made ready for manufacturing,” the statement added.
Haffkine Biopharmaceuticals Ltd has asked for 12 months to complete the task. However, the government has asked them to expedite and complete the task within 6 months. The facility will have a capacity of 20 million doses per month, once functional, the government said.
According to the government the current production capacity will be doubled by May-June 2021 and increased nearly 6-7 fold by July-August 2021. “Increasing the one crore doses a month in July-August. It is expected to reach nearly 10 crore doses per month by September, 2021,” the statement further said.
Apart from that, the financial support of Rs 65 crore has been granted to Bharat Biotech's new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
Covaxin is one of the two vaccines that is being currently administered in India. Manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, it uses an inactivated virus.
The state-run Public Sector Undertaking (PSUs) will manufacture the drug on the basis of transfer of technology. “The government of India will be supporting to prepare their facility to provide 10-15 million doses per month by August-September,” the government said in a statement.
The Department of Science and Technology had on Thursday granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis," the Maharashtra Chief Minister's Office tweeted.
“Financial support to the tune of approximately Rs 65 crore will be provided for this facility to be made ready for manufacturing,” the statement added.
Haffkine Biopharmaceuticals Ltd has asked for 12 months to complete the task. However, the government has asked them to expedite and complete the task within 6 months. The facility will have a capacity of 20 million doses per month, once functional, the government said.
According to the government the current production capacity will be doubled by May-June 2021 and increased nearly 6-7 fold by July-August 2021. “Increasing the one crore doses a month in July-August. It is expected to reach nearly 10 crore doses per month by September, 2021,” the statement further said.
Apart from that, the financial support of Rs 65 crore has been granted to Bharat Biotech's new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
Covaxin is one of the two vaccines that is being currently administered in India. Manufactured by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, it uses an inactivated virus.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.